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ABSTRACT Increasing rates of antibiotic-resistant bacterial infection are one of the
most pressing contemporary global health concerns. The ESKAPE pathogens (Entero-
coccus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter bauman-
nii, Pseudomonas aeruginosa, and Enterobacter species) have been identified as the
leading global cause of multidrug-resistant bacterial infections, and overexpression
of multidrug efflux (MEX) transport systems has been identified as one of the most
critical mechanisms facilitating the evolution of multidrug resistance in ESKAPE
pathogens. Despite efforts to develop efflux pump inhibitors to combat antibiotic re-
sistance, the need persists to identify additional targets for future investigations. We
evaluated evolutionary pressures on 110 MEX-encoding genes from all annotated
ESKAPE organism genomes. We identify several MEX genes under stabilizing selec-
tion—representing targets which can facilitate broad-spectrum treatments with evo-
lutionary constraints limiting the potential emergence of escape mutants. We also
examine MEX systems being evaluated as drug targets, demonstrating that diver-
gent selection may underlie some of the problems encountered in the development
of effective treatments—specifically in relation to the NorA system in S. aureus. This
study provides a comprehensive evolutionary context to efflux in the ESKAPE patho-
gens, which will provide critical context to the evaluation of efflux systems as antibi-
otic targets.
IMPORTANCE Increasing rates of antibiotic-resistant bacterial infection are one of
the most pressing contemporary global health concerns. The ESKAPE pathogen
group represents the leading cause of these infections, and upregulation of efflux
pump expression is a significant mechanism of resistance in these pathogens. This
has resulted in substantial interest in the development of efflux pump inhibitors to
combat antibiotic-resistant infections; however, no widespread treatments have
been developed to date. Our study evaluates an often-underappreciated aspect of
resistance—the impact of evolutionary selection. We evaluate selection on all anno-
tated efflux genes in all sequenced ESKAPE pathogens, providing critical context for
and insight into current and future development of efflux-targeting treatments for
resistant bacterial infections.
KEYWORDS antibiotic resistance, drug resistance evolution, efflux pumps, pathogens
The widespread and inappropriate use of antibiotics as therapeutic agents forhumans and domestic animals and as growth promoters in agriculture has led to an
increased prevalence of multidrug-resistant (MDR) bacteria in the environment. Short-
comings in the pipeline for the discovery, development, and approval of new antibi-
otics to treat the array of pathogens resistant to existing antibiotics exacerbate the
looming health crisis (1). The threat to public health is immediate (2), with MDR
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infections leading to 700,000 deaths globally in 2016 (3). If the trajectory continues,
MDR cases are expected to rise to 10 million by 2050—more fatalities than both cancer
and HIV/AIDS combined cause today (3).
The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter
spp.), noted for their propensity to “escape” the inhibitory action of traditional antibi-
otic drugs, cause a significant proportion of nosocomial and biofilm-mediated infec-
tions (4–6). Upregulated expression of multidrug efflux (MEX) pumps is one mechanism
by which the ESKAPE pathogens become resistant. These MEX pumps act by expelling
compounds, including antibiotics, from the intracellular compartment/intermembrane
space at a high rate, preventing drug concentrations from reaching inhibitory concen-
trations (7–12). Six superfamilies of MEX pumps have been identified: the ATP-binding
cassette (ABC) family, the small multidrug resistance (SMR) family, the major facilitator
superfamily (MFS), the resistance-nodulation-division (RND) family, the multidrug and
toxic compound extrusion (MATE) family, and the recently recognized sixth superfam-
ily, the proteobacterial antimicrobial compound efflux (PACE) family, although this
group of MEX pumps is known only to efflux cationic biocides (13, 14).
As MEX pump upregulation is critical to the evolution of MDR phenotypes across a
broad array of pathogens, MEX pumps are attractive targets for drug development and
discovery (15). Efflux pump inhibitors (EPIs) can be combined with antimicrobial agents
in order to treat otherwise MDR infections (16), rendering previously resistant bacteria
susceptible to multiple classes of antibiotic agents (17). While many potential EPIs have
been described in the literature (16–19), challenges associated with EPIs as therapeutic
compounds, including toxicity to patients, have prevented their widespread use.
Despite these challenges, there has been a renewed interest in these compounds to
treat MDR infections (15). Studies have taken steps to address substrate specificity (20,
21), but few studies have considered the conservation of genes encoding efflux pumps
at the strain level (18, 22, 23). Examining how these genes are conserved prior to EPI
development can ensure that potential EPIs will target the widest range of pathogenic
strains and minimize the likelihood of promoting escape mutants.
In this study, we take an evolutionary approach to evaluate selection across MEX
systems in the ESKAPE pathogens to identify genes described by models of purifying
selection (i.e., evolution that eliminates deleterious alleles from a population), stabiliz-
ing selection (i.e., selection favoring intermediate rather than extreme variants), neutral
selection (i.e., stochastic evolution), and diversifying selection (i.e., selection favoring
the tails of a trait distribution resulting in adaptive divergence). In doing so, we examine
the breadth of likely applications for potential EPIs targeting each of these specific MEX
systems. This identification of conservation provides a comprehensive evolutionary
context to all MEX pumps in the ESKAPE pathogens, along with insights into the
evolutionary origins of these important structures.
RESULTS
We took an in silico approach to identify genes encoding ESKAPE pathogen efflux
pumps undergoing evolutionary pressure. Using only those MEX genes with previously
demonstrated involvement in antibiotic resistance, chromosomal genes encoding com-
plete or partial efflux pumps were screened for evidence of selection by calculating the
ratio of nonsynonymous to synonymous mutations (dN/dS) and evaluating coevolution
with other efflux pump genes from the same organism, using comparisons of phylo-
genetic topology evaluated by pairwise calculation of Robinson-Foulds (RF) distances.
Preliminary analysis of the selected genes for DNA polymorphisms revealed overall
low diversity as determined by the proportion of variable sites (see Table S2 in the
supplemental material). An assessment of evolutionary pressure acting upon the
selected genes revealed that across genes from all ESKAPE pathogens, there was
evidence for selection at a high number of sites (proportion of sites at which there is
evidence for purifying selection [p0  90%]; see Fig. 3 and Table S4) for nearly half
(51/110) of efflux pump-associated genes, although the distribution and ranges of p0
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values were highly variable across each pathogen (Fig. 1; see also Fig 3 and Table S3).
Ten genes were classified as being under moderate selection (75%  p0  90%), with
the remaining 49 genes analyzed having a low (p0  75%) proportion of sites detected
as being under selection.
Of the genes indicating low proportions of sites under purifying selection, 38
exhibited statistically significant evidence for purifying selection based on the
likelihood-ratio test of a nearly neutral model (M1a), assuming only neutral and
purifying selection, and a positive pressure model (M2a) (Table S4). Statistically signif-
icant purifying selection was also observed for two genes classified as under moderate
selection as well as seven classified as under high selection.
To identify potential targets for EPIs, the selection models for genes of each
pathogen were examined more closely. Of the selected efflux pump genes from
E. faecium, msrC had the highest evidence for selection, with all sites classified as under
selection. Moderate selection was observed for efrA and efmA, while evidence for
positive selection was observed for efrB.
Evidence for purifying selection was found in S. aureusMDR efflux pump genes, with
six of the nine genes having p0 values greater than 90% (Table S4). Not among these
is the gene encoding the well-characterized MFS efflux pump NorA (24, 25), which was
under moderate selection, along with two less-studied genes, lmrS and sav1866. Genes
fitted better by the more complex model M2a included norA, lmrS, and mepA.
All identified efflux pump genes for K. pneumoniae were of the RND superfamily of
efflux pumps. Purifying selection was identified for the majority (13/18) of K. pneu-
moniae genes, consisting of all complete RND systems except for the copper efflux
system, cusABCF. The gene eefC, encoding the outer membrane protein for the eefABC
system, was classified as having moderate selection but was close to the determined
classification cutoff for high levels of purifying selection (p0  0.88).
A. baumannii also had a high number of genes identified as highly conserved (14/21)
but not the adeABC efflux pump system known to not be well expressed in wild-type
strains. Of the genes defined in this paper as experiencing moderate or low levels of
selection, half were of the MFS superfamily of efflux pumps, while the remaining four
consisted of aceI, a member of the PACE superfamily, and all three components of the
adeABC RND pump. No genes demonstrated a statistically significant difference in
model fit between the two models.
With 39 identified efflux pump genes, including 36 of the RND superfamily, P. aerugi-
nosa had the highest count of genes analyzed, resulting in a wide range of p0 values
FIG 1 Distribution of proportion of variable sites which fit a model of stabilizing selection (p0 scores)
calculated for all MEX pump-encoding genes from each pathogen. The width of each object represents
the density of the data for each pathogen. This illustrates a general pattern of high conservation of MEX
genes in S. aureus and K. pneumoniae, with broader variation in other groups.
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(Fig. 1). These values exhibited three main clusters, corresponding to a group of high,
moderate, and low selection. Included among the highly conserved genes was oprM,
the outer membrane protein affiliated with at least four identified RND efflux pump
systems in P. aeruginosa. Additionally, high p0 values were calculated for several
complete efflux pump systems, such as mexVW-oprM and triABC-oprM/triABC-opmH, as
well as genes encoding the single-protein efflux pumps PmpM and EmrE. Despite these
exceptions, the majority of efflux pump genes are not strongly under selection, with
23/39 genes being classified as low or moderate. Of the genes classified as being under
low selection, all but three exhibited significant evidence for positive selection (Ta-
ble S4).
Unlike other ESKAPE pathogens, Enterobacter spp. are a grouping based on the
entire genus, resulting in genomes from multiple operational taxonomic units com-
pared in this analysis. Genes identified for this grouping had only one representative
identified as under high selection (acrD), one under moderate selection (eefC), and all
16 other genes classified as under low selection, the majority of which (11/16) showed
evidence for statistically significant positive selection.
We used RF topological distances to compare gene trees for each pathogen and
examine the presence of a possible shared evolutionary history. With a few notable
exceptions, normalized RF scores indicate that most of the distances calculated be-
tween gene trees were high (approaching 1), indicative of independent evolutionary
histories (Fig. 2). However, low levels of polymorphism were detected in many genes
(Table S2), suggesting that the observed RF distances are likely impacted by a lack of
phylogenetic resolution in many comparisons, potentially resulting in a limited power
of the analysis in these cases (26). Thus, the observed high RF scores should be
interpreted with caution.
Within the genes identified for K. pneumoniae, 24 out of 306 gene pairs had a
calculated RF distance of 0, meaning phylogenetic topologies identical and suggesting
possible coevolution (Fig. 2). These genes having RF distances of zero included sets of
the same RND components: periplasmic adaptors acrA, eefA, and acrE; inner membrane
transporters acrB, acrD, acrF, and eefB; and outer membrane protein genes cusC and
eefC. Additionally, phylogenetic topologies were identical for the components of the
mdtABC and oqxA. Identical topologies were also identified between two gene tree
comparisons, mexX-mexG and mexY-mexH, from P. aeruginosa. All other pathogens had
ranges of RF distances that did not include zero (Fig. 2).
DISCUSSION
Despite being a fundamentally evolutionary process, the role of evolution is often
underappreciated in the development of strategies to combat antibiotic resistance.
Examining potential drug targets from an evolutionary perspective provides insight
into the likely effectiveness of treatments impacting a selected target. Given the
pressing need and high costs for establishing new ways to treat antibiotic-resistant
infections, additional screening of potential treatments can prevent investing of re-
sources in drugs that are unlikely to be broadly effective at treating resistant infections.
Consideration of the results from this analysis provides a basis for the development of
evolutionary robust and broadly effective methods to treat MDR infections in the face
of a looming health crisis.
EPIs targeting the efflux pumps encoded by genes that we have identified as being
under purifying selection have already been developed for several MEX systems. For
example, msrC, the only gene identified from E. faecium as a potential good target, has
previously been proposed as a potential drug target, as reductions in the MICs of
macrolide antibiotics were demonstrated (27). However, questions regarding the dis-
tribution of this gene raised questions regarding the potential of msrC as a drug target
(28). This analysis suggests that not only is some form of this gene present in all
sequenced genomes of E. faecium but also that the gene is under stabilizing selection
in these genomes and could make a good target for treating MDR E. faecium.
Although Enterobacter spp. and K. pneumoniae share the same list of efflux pumps
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FIG 2 Distribution of Robinson-Foulds distances (RFD) calculated from phylogenetic trees generated for each gene in each pathogen. This demonstrates
a general lack of support for coevolution of MEX genes in most cases, with the exception of some analogous genes in P. aeruginosa and K. pneumoniae,
suggesting that these pumps may result from recent gene duplication events.
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(Fig. 3), no genes were identified as being under selection for Enterobacter spp. while
most genes from K. pneumoniae were classified as highly conserved. It is likely that the
genus-level analysis of Enterobacter spp. resulted in higher genetic variation (average
nucleotide diversity  0.16) than that for K. pneumoniae (average nucleotide diver-
sity 0.02). This discrepancy limits the ability to directly compare these groups, further
raising questions regarding the grouping of this genus as one class of ESKAPE patho-
gens, as individual species may have different mechanisms and evolutionary pressures
acting upon them.
The acrAB-tolC system in Escherichia coli has received a lot of attention as a potential
drug target to treat resistant infections (17, 29), including the use of the FDA-approved
antipsychotic medication pimozide (30). This system is also found in both Enterobacter
spp. and K. pneumoniae, is comparable with the adeABC and adeIJK systems in A. bau-
mannii (31), and was found in this analysis to likely to be a good candidate for
FIG 3 A selection map showing the ESKAPE species, genes tested, and proportion of sites under stabilizing selection. Color
indicates the relative strength of stabilizing selection on each gene in each species.
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treatment with EPIs. While a number of additional genes were identified here as good
candidates from K. pneumoniae and A. baumannii, little research has gone into devel-
oping EPIs for additional systems.
EPIs have been developed for treating MDR S. aureus, but none have proven to be
a reliable treatment. One common target for EPI development is norA, shown in
this analysis to be highly variable and under positive selection (see Table S4 in the
supplemental material). Large amounts of variation in this gene have been observed
previously (32, 33), possibly contributing to the failures of tested EPIs. Consideration of
evolutionary selection has the potential to greatly increase the success of future EPI
trials. Thus, while norA is highly effective at the removal of antibiotics, it may be difficult
to target with EPIs due to genetic inconsistency.
MEX systems in P. aeruginosa have been heavily studied, as they are prevalent in
MDR strains. However, our findings suggest a lack of evolutionary pressure observed for
a majority of these systems. One possible explanation for the discrepancy between
what is known to be an important set of systems and the lack of evolutionary pressure
is the possibility of redundancy within the efflux pumps. The sheer volume of efflux
pump systems, many of which have components that are interchangeable with other
systems, might alleviate the evolutionary pressure observed for many of the other
systems, making MEX systems from P. aeruginosa more variable across strains.
In addition to screening for selective pressure, we used RF distances to measure the
similarity/dissimilarity of phylogenies for each gene, providing for evidence of shared or
independent evolutionary history. As MEX pumps are multiprotein/gene structures,
coevolution indicates a tight link between pump components, and thus, mutations in
individual components of MEX pumps affect the function of the structure as a whole.
Conversely, independent evolutionary histories may indicate that pumps had been
recently coopted from other functions and are able to respond rapidly to novel
evolutionary selection.
Despite limitations due to low overall genetic diversity in the genes analyzed (see
Table S2), a number of RF comparisons in K. pneumoniae and P. aeruginosa demon-
strated identical phylogenetic topologies. These genes are largely analogous genes in
distinct MEX pump systems, which is indicative of these distinct pump systems arising
from relatively recent gene duplication events. The possibility of spontaneous emer-
gence of novel MEX systems may pose challenges for treating and monitoring MDR
organisms, but the shared evolutionary history of distinct MEX systems may also mean
that similar strategies may be used to target multiple MEX pumps in these pathogens.
MATERIALS AND METHODS
Data collection. Publicly available genome coding sequences for each ESKAPE pathogen were
downloaded from NCBI (accessed on 14 July 2017). We selected complete genomes only, resulting in 545
genomes from E. faecium (n  26), S. aureus (n  168), K. pneumoniae (n  137), A. baumannii (n  79),
P. aeruginosa (n  80), and Enterobacter spp. (n  55), including representatives from available
operational taxonomic units within the genus (see Table S1 in the supplemental material). Downloaded
coding sequences were converted to Basic Local Alignment Search Tool databases using BLAST (34).
Chromosomally located genes (n 110) encoding efflux pumps and their components from all of the
ESKAPE pathogens, as listed in the work of Li et al. (35), were included in the analysis. The amino acid
sequence for each of the identified genes was downloaded from the UniProt knowledge base (36) using
the reference genome for each pathogen. These sequences were then used to identify analogous genes
from the downloaded coding sequences for each pathogen using BLAST (34). Duplicate gene se-
quences within a genome were screened for similarity and in all cases were identical, allowing only one
identified gene sequence to be used for analysis.
Data analysis. Sequences within the genomes with the top hit identified from BLAST output from
each genome were aligned for each gene using MUSCLE v3.8.31 (37). The resulting alignments were used
to analyze individual genes for DNA polymorphisms with DnaSP v5 (38) and to construct unrooted
maximum likelihood trees using RAxML (39) with a bootstrap value of 1,000.
Genes were screened for evidence of evolutionary pressures using the Phylogenetic Analysis by
Maximum Likelihood (40) software package. Positive selection was tested for each gene based on the
ratio of nonsynonymous to synonymous mutations per site (  dN/dS) using the codeml program.
Variable sites in each gene alignment were fitted to both a nearly neutral model (M1a), assuming only
neutral and purifying selection, and a positive-pressure model (M2a), allowing sites to be classified as
either purifying, neutral, or under positive selection. All models were fitted using a single  value for all
lineages and average nucleotide frequencies at the third codon position.
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Genes were assessed for evidence of evolutionary pressure by determining the proportion of sites at
which there is evidence for purifying selection (p0) under M2a. Sites with high p0 values (p0  90%) are
classified here as highly conserved and thus are more likely to be stable drug targets across multiple
pathogen strains. The 2 analysis of likelihood ratios of the two models was used to calculate the
statistical significance of fitting the more complex model (M2a) compared to the simpler model (M1a) to
suggest an observed positive, or diversifying, for the genes.
To assess if any combination of genes exhibited coevolution, Robinson-Foulds (RF) distances (41)
were calculated pairwise for all phylogenies within ESKAPE groups using the phytools package (42) in R
statistical software (43).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
mSystems.00024-18.
TABLE S1, XLSX file, 0.1 MB.
TABLE S2, PDF file, 0.1 MB.
TABLE S3, PDF file, 0.5 MB.
TABLE S4, PDF file, 0.3 MB.
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